Podcast: Play in new window | Download (Duration: 34:01 — 77.9MB)
Subscribe: Apple Podcasts | Spotify | RSS
On this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, sits down with David Harel, CEO and Co-founder of CytoReason. CytoReason uses AI-powered disease models to transform drug discovery and development, offering pharmaceutical companies insights that reduce both time and costs in bringing new therapies to market.
David shares his journey from private equity to co-founding CytoReason—an idea sparked on a beach in Israel. They discuss why no one had applied molecular data this way before, how CytoReason’s models differ from existing approaches, and the benefits they offer in accelerating drug development. They also delve into the evolving role of AI in drug discovery, the transformative potential it holds, and the critical challenges the industry will face as the field scales.
Reflecting on the importance of diverse thinking in this fast-evolving space, David notes,
“Diversity of opinions is critical to making things work. You need diverse perspectives to distill the truth before it’s delivered to the customer, who is highly educated and smart. Without tough questions being asked openly, things can fall apart quickly.”
David also offers three key pieces of advice for entrepreneurs looking to enter the intersection of AI and life sciences today.
Subscribe or follow Biotalk on Apple Podcasts | Spotify.
Timestamps:
1:14 To start, nothing in your background said AI or disease biology, how did you decide to work in this space and what motivated you to co-found CytoReason?
5:50 Why hadn’t anyone done this before with molecular data? And how was it different from what was being done?
6:54 Did the vision for CytoReason stay the same or evolve?
7:30 The big question, where do you get the data and is it proprietary?
10:28 What do CytoReason’s models do? What is the benefit and how does this help drug development?
13:50 How are you thinking about building your business out to tackle the industry?
22:00 How do you foresee the role of AI evolving in drug discovery and development, and what challenges do you anticipate as the field grows?
28:55 What advice would you give to entrepreneurs looking to enter the intersection of AI and life sciences today?